Response to Comments for MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease

This policy covers multi-gene and NGS panel testing for evaluation of suspected BCR‑ABL–negative myeloproliferative diseases and allows concurrent BCR‑ABL and JAK2 testing when a clinician suspects an MPD. CALR testing is covered (and preferred over MPL) but is expected only after a negative JAK2 V617F result unless justified; multi-gene panels are billed as a single unit of service and individual single-gene CPT codes may be used only when tests are performed sequentially. Exceptions and requests for repeat testing require supporting clinical documentation and may be pursued through the appeals process.

"Coverage is provided for multi-gene or NGS panel testing to evaluate suspected BCR-ABL–negative myeloproliferative disease (MPD/MPN) including diagnostic and differential evaluation."

Sign up to see full coverage criteria, indications, and limitations.